Table S1A-D Clinical and demographic data of all patients enrolled in the three selected studies.

Table S1A PMID 15307835-Clinical and demographic data of all patients enrolled in the study.

PMID 15307835									
Patient ID	**BX**	**PBL**	**Age**	**Sex**	**Immunosuppression**	**Histo pathology**	**LD/CAD**	**Scr (mg/dL)**	**Days post TX**
C1	•		38	Female				0.8	
C2	•		42	Male				0.9	
C3	•		35	Female				0.6	
C4	•		39	Female				0.9	
C5	•	•	39	Male				1.2	
C6	•		44	Male				0.8	
C7	•		36	Male				1.2	
C8	•		35	Female				0.8	
C9	•		50	Female				0.6	
AR1	•	•	42	Male	CsA/MMF/P	BanffIIA	CAD	12	285
AR2	•	•	28	Male	FK/MMF/P	BanffIIA	LD	5.9	1467
AR3	•	•	18	Male	CsA/MMF/P	BanffIA	CAD	2.2	119
AR4	•	•	28	Female	FK/MMF/P	BanffIIA	CAD	1.5	366
AR5	•	•	26	Female	CsA/MMF/P	Borderline	CAD	2	278
AR6	•	•	55	Male	SRL/MMF/P	Borderline	CAD	2.9	68
AR7	•	•	35	Male	SRL/MMF/P	BanffIA	CAD	2	184
TX1	•		51	Male	CsA/MMF/P	Normal	CAD	1.5	932
TX2	•		56	Male	CsA/MMF/P	Normal	LD	1.3	911
TX3	•		52	Male	CsA/MMF/P	Normal	CAD	1.2	902
TX4	•		31	Female	CsA/MMF/P	Normal	LD	1.1	651
TX5	•		53	Female	CsA/MMF/P	Normal	LD	1.1	689
TX6	•		32	Male	CsA/MMF/P	Normal	LD	1.6	776
TX7	•		46	Female	CsA/MMF/P	Normal	CAD	1.2	713
TX8	•		61	Male	CsA/MMF/P	Normal	CAD	0.9	733
TX9	•		44	Male	CsA/MMF/P	Normal	LD	1.8	718

Patient ID	BX	PBL	Age	Sex	Immunosuppression	Histopathology	LD/CAD	Scr (mg/dL)	Days post TX
TX10	•		21	Male	CsA/MMF/P	Normal	CAD	1.5	674
TXPBL1		•	38	Male	CsA/MMF/P		CAD	1.4	461
TXPBL2		•	57	Female	FK/MMF/P		LD	1.3	42
TXPBL3		•	65	Male	CsA/MMF/P		CAD	1.5	213
TXPBL4		•	65	Female	FK/MMF/P		CAD	0.8	246
TXPBL5		•	36	Female	CsA/MMF/P		CAD	1.1	1278
TXPBL6		•	68	Male	CsA/MMF/		CAD	1.7	376
TXPBL7		•	39	Male	SRL/MMF/P		CAD	0.9	36
TXPBL8		•	61	Female	CsA/MMF/P		CAD	0.9	1491
TXPBL9		•	46	Male	SRL/MMF/P		LD	1.2	81
NR1	•	•	55	Male	CsA/MMF/P	CNI toxicity	LD	1.7	456
NR2	•	•	38	Male	FK/MMF/P	CNI toxicity	LD	2.3	155
NR3	•	•	61	Male	SRL/MMF/P	ATN	LD	5.2	11
NR4	•	•	43	Male	CsA/MMF/P	CNI toxicity	CAD	3.8	262
NR5	•	•	35	Male	CsA/MMF/P	ATN	CAD	6.3	16
NR6		•	35	Female	FK/MMF/P	CNI toxicity	CAD	2.6	37
NR7		•	44	Male	SRL/MMF/P	ATN	CAD	6.3	40
NR8	•	•	22	Female	FK/MMF/P	FSGS	LD	3.3	78
NR9		•	58	Male	CsA/MMF/P	ATN	CAD	5	47

Table S1A legend: BX, biopsy; PBL, peripheral blood lymphocytes; CsA, cyclosporine; MMF, mycophenolate mofetil; P, prednisone; FK, tacrolimus; SRL, sirolimus; CAD, cadaveric; LD, live donor; Scr, serum creatinine; ATN, acute tubular necrosis; CNI, calcineurin inhibitor; FSGS, focal segmental glomerulosclerosis.

Table S1B PMID 21672049-Demographic data of donors and recipients stratified by treatment assignment. Continuous data are provided as median (first, third quartile), categorical data are shown as counts.

PMID 21672049			
	Tacrolimus	**Placebo**	**P-value**
Donor	13	13	
Gender (f/m)	5-Aug	7/6 0	691*
Pretreatment steroids (no/yes)	8-May	9-Apr	1.000†
Cause of death	2/9/4	3/9/2	0.762†
(else/intracranial haemorrhage/trauma)			
Comorbidities	1/6/1/4/3/3	0/3/2/0/6/3	0.231†
(DM/hypertension/MCI/stroke/none/unknown)			
Age [years]	53 (38, 64)	50 (33, 57)	0.396
Steatosis in donor liver [%]	1 (0, 5)	5 (0, 10)	0.554
ALT [IU/l]	20 (18, 50)	42.5 (16, 61)	0.608
AST [IU/l]	34 (29, 61)	35 (23, 76)	0.959
Bilirubin [mg/dl]	0.60 (0.43, 0.83)	0.54 (0.30, 0.80)	0.758
Creatinine [mg/dl]	0.75 (0.62, 1.20)	0.99 (0.70, 1.78)	0.238
INR	0.0(0.0, 1.2)	0.0 (0.0, 1.1)	0.887
Quick value [%]	71 (65, 89)	82 (73, 99)	0.397
PTT [s]	35 (22.4, 38.2)	36.2 (24, 47)	0.699
Recipient	13	13	
Gender (f/m)	9-Apr	10-Mar	1.000†
Age [years]	55.5 (50, 59)	55 (53, 60)	0.959
CIT [h]	8.0 (6.3, 9.0)	7.8 (5.8, 9.8)	0.878
MELD	20 (16; 23)	16 (14; 20)	0.137
Indication for OLT			
PHCC	2	3	1.000†
HCCA	1	3	0.593†
ALCI	4	6	0.688†
PBCI	2	1	1.000†
OTCI	3	0	0.220†
AUCI	1	0	1.000†
Operation data			
Operation time [min]	330 (260; 445)	340 (285; 420)	0.719
WIT [min]	71 (65; 78)	77 (70; 90)	0.157
Blood products			
Packed cells	0 (0; 4)	2 (0; 8)	0.572
FFP	6 (2; 10)	8 (6; 12)	0.457
Platelets	0 (0; 0)	0 (0; 0)	0.939

Table S1B legend: AST, aspartate transaminase; ALT, alanine transaminase; PTT, partial thromboplastin time; INR, international normalized ratio; MELD, model for end-stage liver disease; OLT, orthotopic liver transplantation; PHCC, post hepatitis C cirrhosis; HCCA, hepatocellular carcinoma; ALCI, alcoholic cirrhosis; PBCI, primary biliary cirrhosis; OTCI, other cirrhosis: unknown causes; AUCI, autoimmune cirrhosis; WIT, warm ischaemic time; FFP, fresh frozen plasma. *Chi-square test, †Fisher's exact test

Table S1C PMID 21114641-Demographics of SRL and CSA recipients

PMID 21114641-Demographics of SRL and CSA recipients									
Study group	Recipient age at inclusion (years)[1]	Recipient gender	Donor age[1],*	Time posttransplant [1],* (years)	Graft number	A + B + DR mismatches	Serum creatinine at inclusion[1]	Proteinuria at inclusion[1]	Drug trough levels[2]
SRL (n = 4)	61 (8.9)	13 Male 11 female	50.3 (11.7)	9.75 (2.6)	23 First 1 third	≤2: 17 ≥3: 7	1.43 (0.35) mg/dL	710 (769) mg/day	10 (1.7) ng/mL
CSA (n = 3)	61.1 (14)	9 Male 4 female	23.8 (12.4)	16.4 (3.3)	11 First 2second	≤2: 5 ≥ 3: 6 NA: 2	1.4 (0.6) mg/dL	519 (452) mg/day	119 (36) ng/mL

Table S1C-D legend *p-Value <0.05.[1]Mean (SD).[2]Mean (SD) of drug trough levels obtained during the 6 months prior to inclusion.

Table S1D PMID 21114641-Immunosuppressive regimens prior to the adoption of monotherapy of SRL and CSA recipients enrolled in the study

PMID 21114641- Immunosuppressive regimens prior to the adoption of monotherapy			
Study group	Induction therapy	Maintenance immunosuppression[1]	Treatment assignment
CSA	–	SRL + CSA	De novo
CSA	–	Tac + CSA	De novo
CSA	–	CSA	De novo
CSA	–	CSA	De novo
CSA	–	CSA	De novo
CSA	ALS	CSA	De novo
CSA	–	CSA	Conversion from Tac
CSA	ALS	CSA	De novo
CSA	ALS	CSA	De novo
CSA	–	SRL + PDN + CSA	Conversion from Tac
CSA	–	CSA	De novo
CSA	–	CSA + PDN	De novo
CSA	–	SRL + PDN	Conversion from SRL
SRL	–	SRL + CSA + CSA	Conversion from CSA
SRL	–	SRL + PDN	De novo
SRL	–	SRL + PDN	De novo
SRL	–	SRL + CSA	De novo
SRL	–	SRL + CSA	Conversion from CSA
SRL	–	SRL + PDN	De novo
SRL	–	SRL + CSA	Conversion from CSA
SRL	–	SRL + PDN	Conversion from CSA
SRL	–	SRL + CSA + PDN	Conversion from CSA
SRL	–	SRL + PDN	Conversion from CSA
SRL	–	SRL + CSA + PDN	De novo
SRL	–	SRL + CSA	Conversion from CSA

SRL	–	SRL + CSA	Conversion from CSA
SRL	–	SRL + PDN	Conversion from CSA
SRL	–	SRL + PDN	Conversion from CSA
SRL	–	SRL + PDN	Conversion from CSA
Study group	Induction therapy	Maintenance immunosuppression[1]	Treatment assignment
SRL	–	SRL + PDN	Conversion from CSA
SRL	–	SRL + PDN	De novo
SRL	–	SRL + PDN	Conversion from CSA
SRL	–	SRL + CSA	Conversion from CSA
SRL	–	SRL + PDN	Conversion from CSA
SRL	–	SRL + PDN	De novo
SRL	BAS	SRL + CSA	Conversion from CSA

Table S1D legend Tac = tacrolimus; PDN = prednisone; CSA = cyclosporine A; SRL = sirolimus; ALS = polyclonal anti-lymphocyte serum; BAS = basiliximab; OKT3 = muronomab-CD3.[1]Maintenance immunosuppressive regimen 1 year prior to initiation of CSA or SRL monotherapy.